Open Access

Intracerebroventricular injection of RFRP-3 delays puberty onset and stimulates growth hormone secretion in female rats

  • Xinghui Han1,
  • Yuanyuan He1,
  • Gulan Zeng2,
  • Yonghong Wang1,
  • Wen Sun1,
  • Junchao Liu1,
  • Yanyan Sun1 and
  • Jian Yu1Email author
Reproductive Biology and Endocrinology201715:35

https://doi.org/10.1186/s12958-017-0254-5

Received: 19 October 2016

Accepted: 27 April 2017

Published: 2 May 2017

Abstract

Background

Puberty onset is a complex, organized biological process with multilevel regulation, and its physiopathological mechanisms are yet to be elucidated. RFRP-3, the mammalian ortholog to gonadotropin-inhibitory hormone, is implicated in inhibiting the synthesis and release of gonadotropin in mammals. However, it is unclear whether RFRP-3 participates in regulating pubertal development.

Methods

This study investigated the functional significance and regulatory mechanism of hypothalamic RFRP-3 neuropeptide in the onset of puberty in young female rats. On postnatal day 22, we implanted cannulas into the lateral ventricles of female rat pups. From postnatal day 28 to postnatal day 36, the intracerebroventricular injection of RFRP-3, or vehicle, was conducted twice a day. To investigate whether puberty onset was affected, we examined the body weight, age of vaginal opening, serum hormone levels, uterus and ovary development, and hypothalamic Kiss-1 mRNA expression.

Results

Intracerebroventricular injection of RFRP-3 significantly decreased the serum concentrations of luteinizing hormone and estradiol, delayed uterine maturation, and postponed the time of vaginal opening. This study suggests that RFRP-3 can delay the onset of puberty in young female rats; the expression of Kiss-1 mRNA is potently inhibited in the RFRP-3 group. Moreover, our data show that RFRP-3 elevates serum growth hormone levels.

Conclusions

These data suggest that intracerebroventricular injection of RFRP-3 significantly delays the onset of puberty in female rats. Additionally, RFRP-3 may be associated with prepubertal rise in the secretion of growth hormone.

Keywords

RFRP-3 Puberty onset Kiss-1 GH

Background

Puberty is the process of physical changes through which a child’s body matures into an adult body capable of sexual reproduction. The onset of puberty is a well-organized biological process controlled by the reproductive neuroendocrine systems [1, 2]. It is governed by high-frequency hypothalamic gonadotropin-releasing hormone (GnRH) pulsing [36]. The release of GnRH leads to the secretion of gonadotropins, luteinizing hormone (LH), and follicle-stimulating hormone (FSH), which target the gonads to trigger puberty. Previous studies reported that several upstream neuropeptides, such as kisspeptins [68], neuropeptide Y (NPY) [9], leptin [10], substance P (SP) [11], neurokinin B (NKB) [1214], and RF-amide related peptide-3(RFRP-3) [15], were implicated in the control and modulation of GnRH secretion. However, the changes and interrelationships of these modulators before and during puberty remain poorly understood.

Kisspeptins, encoded by the hypothalamic Kiss-1 gene, are stimulators of the reproductive axis and play a critical role in the reproductive function [16, 17]. Kisspeptins potently elicit the release of gonadotropin, primarily through the stimulation of GnRH secretion. Numerous studies suggest that the kisspeptin/GPR54 system is the trigger for puberty onset [1821].

RFRP-3, the mammalian ortholog of avian gonadotropin-inhibitory hormone (GnIH), is an inhibitor of the reproductive axis [2225]. GnIH, which potently inhibits the release of pituitary gonadotropin, was first discovered in the avian species in 2000 [22]. RFRP-3 neuron fibers are found in close apposition to GnRH, kisspeptin, and growth hormone-releasing hormone (GHRH) neurons in the hypothalamus, suggesting a possible functional relationship among them [2628]. Approximately 60–80% of GnRH neurons have RFRP-3 appositions in female prepubertal rats [29]. Additionally, GnRH and kisspeptin neurons can express the RFRP-3 receptor, GPR147 [28, 30]. This suggests that RFRP-3 may inhibit the reproductive axis by acting directly on kisspeptin neurons, GnRH neurons, or both. Furthermore, controversy remains over a possible direct effect of RFRP-3 at the level of the pituitary. RFRP-3 altered the levels of LH, it has been previously revealed. Several studies have demonstrated that the injection of RFRP-3 into the lateral ventricle, or intravenously suppresses LH secretion in adult rats, mice, hamsters, and sheep [25, 27, 3033].

However, the above-mentioned studies were performed in adult mammals and only explored the instantaneous effect of a single injection of RFRP-3. There is little evidence showing that RFRP-3 plays a definite role in the timing of pubertal onset in young mammals. A study conducted in 2014 suggested that the presence of variants in the genes encoding human RFRP-3 and GPR147 is not associated with the occurrence of GnRH-dependent pubertal disorders [34]. The pubertal timing was not altered in GPR147 (NPFF1R) knockout (KO) mice [35]. These studies indicated that the RFRP-3/GPR147 pathway may play secondary, modulatory roles in the regulation of puberty onset. However, RFRP-3 pathways in the hypothalamus were associated with advanced puberty in female rats exposed to bisphenol A [29]. RFRP-3 injection significantly inhibited the release of LH, in an estradiol-dependent manner, in prepubertal female mice [36]. This suggested that hypothalamic RFRP-3 may be involved in the regulation of the reproductive axis in young animals.

Therefore, the modulatory effect of the RFRP-3 on the onset of puberty requires further investigation. In this study, we injected RFRP-3 into the lateral ventricles and compared the alteration in pubertal development in prepubertal female rats.

Methods

Animals

A total of 18 prepubertal female Sprague-Dawley rats (50–60 g), weaned on postnatal day (PND) 21, were purchased from the Shanghai SLAC Laboratory Animal Co., Ltd [license number: SCXK (Shanghai) 2012-0002]. The animals were housed in the animal center of the Children’s Hospital of Fudan University. The rats were provided with individual cages, standard rodent diet and water, and were maintained at an appropriate temperature (22 °C ± 2 °C) and humidity (55% ± 1.5%) and 12/12-h light/dark cycle. All procedures were approved by the Fudan University Animal Care and Use Committee in accordance with the National Institutes of Health Guide for Care and Use of Laboratory animals.

Experimental design

Eighteen female rats were randomly divided into an RFRP-3 group, a Vehicle group, and a Normal group, with six rats per group. On PND 22, all the rats in the RFRP-3 and Vehicle groups received a cannula implantation into the lateral ventricle, while no treatment was performed on the rats in the Normal group. After the surgery, the rats were allowed to recuperate for 6 days to the cerebrovascular barrier to recover. From PND 22, the rats were weighed and the vaginal opening (VO) was observed every morning. From PND 28, the rats in the RFRP-3 group were injected with RFRP-3 at the dose of 0.5 μg/5 μl twice a day; the rats in the Vehicle group were injected with 5 μl physiologic saline twice a day; no treatments were performed on the rats in the Normal group. On PND 36, the rats were anesthetized with 5% chloral hydrate (0.8 ml/100 g body weight) and blood was drawn 30 min after the last intracerebroventricular(ICV) injection. Subsequently, the blood, hypothalami, uteri, and ovaries were immediately harvested.

Cannula implantation into the lateral ventricle

On PND 22, a 3-mm cannula (Shenzhen RUIWODE Life Technology Co., Ltd, China) was inserted vertically into the lateral ventricle of the rats (AP = -0.8 mm, Lat = -1.2 mm, DV = -3.6 mm, relative to the bregma), and fixed, using dental cement, onto the surface of the skull. The correct location for the cannula implantation was determined histologically at the end of the procedure.

ICV injection

RFRP-3 (also called NPVF; 048-33, Phoenix Pharmaceuticals, Inc., USA) was dissolved in sterile physiologic saline to a final concentration of 0.1 μg/μl. Polyethylene(PE) tubing was attached to a 3.6 mm inner pipe (Shenzhen RUIWODE Life Technology Co., Ltd) on one end and connected to a 10 μl microsyringe on the other end. The drug was slowly injected into the lateral ventricle and the inner pipe was gently extracted 10 min post-injection.

Validation of the location of ICV injection

At the end of the procedure, the rats in the Vehicle and RFRP-3 groups were injected with 5 μl trypan blue into the lateral ventricles. After the hypothalamus was excised, the remaining brain tissue was fixed in 4% paraformaldehyde for 24 h. The brain tissue was sectioned at the thickness of 50 μm to assess whether trypan blue had been successfully injected into the lateral ventricle. Experimental data from each rat recorded whether the dye was successfully injected into the lateral ventricle.

Uterine and ovarian histology

The uteri and ovaries were immediately excised and weighed to evaluate the organ coefficients, which were determined by the formula: [organ wet weight (g)/body weight (g)] × 10-4. The uteri and ovaries were fixed in 4% paraformaldehyde, and embedded in paraffin. The paraffin-embedded tissues were then sectioned at 4 μm and stained with hematoxylin-eosin (HE). The endometrial thickness was measured using a Leica microscope (four fields were selected to obtain the mean endometrial thickness).

Serum hormone enzyme-linked immunosorbent assay

Blood samples were collected from the jugular veins and centrifuged at 1200 × g for 5 min; the serum was preserved in a -80 °C freezer. ELISA kits (eBioscience, Affymetrix, USA) were used to detect the concentrations of LH, FSH, estradiol (E2), and growth hormone (GH), according to the manufacturer’s instructions.

Reverse Transcription Real-time Quantitative Polymerase Chain Reaction (RT-qPCR) for Kiss-1 and GnRH mRNA

The effects of ICV injection of RFRP-3 on the expression of Kiss-1 and GnRH mRNA in the hypothalami were detected by RT-qPCR. The whole hypothalamus was excised and snap-frozen in liquid nitrogen. Total hypothalamic RNA was extracted using a Direct-zol RNA MiniPrep kit (Zymo Research, USA) and reverse-transcribed into cDNA with an All-In-One RT Master Mix kit (ABM, Canada), according to the corresponding manufacturer’s protocols. All the reactions were performed in triplicate in a 20-μl total reaction volume. The following RT-qPCR amplification program was used: 95 °C, 3 min; then, 40 cycles of 95 °C, 5 s, and 60 °C, 30s(BIO-RAD Real-Time PCR Detection System). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the internal control, and mRNA levels were calculated using the 2-Ct method. The primers were designed and synthesized by Shanghai Generay Biotech Co., Ltd, China (Table 1).
Table 1

Primers used in the study

Gene

Sequence (5′ to 3′)

Product size

GAPDH-F

ACTTTGGCATCGTGGAAGGG

128 bp

GAPDH-R

TGCAGGGATGATGTTCTGGG

Kiss1-F

GGTATGCAGAGAGCAAGCCT

122 bp

Kiss1-R

GATCAGGCGACTGCGGG

GnRH-F

CACTGGTCCTATGGGTTGCG

149 bp

GnRH-R

TCCCTAAGAGGTGAACGGGG

Statistical analysis

Generally, the data with a normal distribution and homogeneity of variance were compared using one-way ANOVA, and comparisons between groups were tested using Duncan’s multiple range tests. Otherwise, data were analyzed by the non-parametric Kruskal-Wallis test using SPSS software (Ver. 19.0; SPSS Inc.). The body weight, age at vaginal opening, wet weight of the uterus and ovary and their organ coefficients, serum hormone concentrations, and levels of Kiss-1 and GnRH mRNA were compared across groups by one-way ANOVA, with treatment as a factor. The results are presented as mean ± SEM. Statistical significance was assumed when P < 0.05.

Results

Effects of ICV injection of RFRP-3 on the body weight

As shown in Fig. 1, the body weight of rats in the different groups gradually increased with age. In all three groups, the body weight of the rats was not significantly different on PND22 (time of cannula implantation), PND28 (time of drug infusion), or PND36 (time of sampling) (Fig. 1, P > 0.05).
Fig. 1

Effects of ICV injection of RFRP-3 on the body weight of female rats. No statistical significance was observed in the body weight among the three groups

Effects of ICV injection of RFRP-3 on the age at vaginal opening

The ICV injection of RFRP-3 exerted a significant effect on the age at vaginal opening (VO). All female rats exhibited vaginal opening before or at PND36. VO was significantly delayed in the RFRP-3 group (Fig. 2, P < 0.01), compared with that in the Vehicle group. The age at VO showed no obvious difference between the Normal and Vehicle groups (Fig. 2, P > 0.05).
Fig. 2

Effects of ICV injection of RFRP-3 on the age at vaginal opening. a The age at VO of the females in the different groups. Data represent means ± SEM. **P < 0.01 versus Vehicle. b The proportion of the females displaying VO at different postnatal ages for the different groups

Effects of ICV injection of RFRP-3 on the wet weight of the uterus and ovary, and their organ coefficients

Compared with the Vehicle group, ICV injection of RFRP-3 for 8 days resulted in a reduction of the uterus wet weight and coefficients (Fig. 3a and c, P < 0.05). There were no significant differences in the ovary wet weight and coefficients between the RFRP-3 and Vehicle groups (Fig. 3b and d, P > 0.05). Moreover, all observed indices showed no statistical differences between the Normal and Vehicle groups (Fig. 3, P > 0.05).
Fig. 3

Effects of ICV injection of RFRP-3 on the wet weight of the uterus and ovary, and their organ coefficients. a Uterus wet weight. b Ovary wet weight. c Uterus coefficient. d Ovary coefficient. Data represent means ± SEM. *P < 0.05 versus Vehicle

Effects of ICV injection of RFRP-3 on morphological changes of the uterus and ovary

The results of HE staining of the uterus and ovary are shown in Fig. 4. A quantitative analysis of uterine morphology was also conducted (Fig. 5). The endometrial thickness of rats in the RFRP-3 group was thinner than that of the Vehicle group (Fig. 5, P < 0.05). There were no obvious differences in the endometrial thickness between the Normal and Vehicle groups (Fig. 5, P > 0.05). These data suggest that ICV RFRP-3 delayed uterine development. By contrast, ovary development was not affected by the injection of RFRP-3. The rats in the three groups presented consistent degrees of ovary development with abundant corpora lutea, and several antral and cystic follicles (Fig. 4d, e, and f).
Fig. 4

a, b, c Effects of ICV injection of RFRP-3 on uterine morphology. Compared with the Vehicle group, endometrial thickness (black arrows) of the RFRP-3 group was distinctly thinner. d, e, f Effects of ICV injection of RFRP-3 on ovarian morphology. Ovarian morphology was distinctly similar across groups. Numerous corpora lutea (yellow arrows) were observed in all three groups. Bar 500 μm

Fig. 5

Effects of ICV injection of RFRP-3 on the endometrial thickness. Data represent means ± SEM. *P < 0.05 versus Vehicle

Effects of ICV injection of RFRP-3 on serum hormone levels

ICV injection of RFRP-3 significantly decreased the serum levels of LH and E2 compared with those of the Vehicle group (Fig. 6b and c, P < 0.01). Serum levels of FSH were significantly elevated in the RFRP-3 group compared with those of the Vehicle group (Fig. 6d, P < 0.01). Additionally, ICV RFRP-3 also significantly elevated the serum levels of GH (Fig. 6a, P < 0.01). There were no observed differences in the levels of GH, FSH, LH, and E2 between the Normal and Vehicle groups (Fig. 6, P > 0.05).
Fig. 6

Effects of ICV injection of RFRP-3 on serum hormone levels. a Serum GH levels. b Serum LH levels. c Serum E2 levels. d Serum FSH levels. Data represent means ± SEM. **P < 0.01 versus Vehicle

Effects of ICV injection of RFRP-3 on the expression of hypothalamic Kiss-1 and GnRH

To examine whether ICV injection of RFRP-3 can affect hypothalamic Kiss-1 and GnRH expression in prepubertal female rats, we used RT-qPCR to measure the abundance of the mRNA of the two genes. Figure 7 shows that ICV RFRP-3 clearly affects the mRNA expression of these genes. The mRNA levels of Kiss-1 and GnRH in the RFRP-3 group were significantly reduced compared with those of the Vehicle group (P < 0.01). There were no differences in the expression of Kiss-1 and GnRH between the Normal and Vehicle groups (P > 0.05).
Fig. 7

Effects of ICV injection of RFRP-3 on the expression of hypothalamic Kiss-1 and GnRH. a Kiss-1 mRNA level. b GnRH mRNA level. Data represent means ± SEM. **P < 0.01 versus Vehicle

Discussion

This study assessed whether hypothalamic RFRP-3 neuropeptide had an inhibitory role in regulating the onset of puberty. We injected RFRP-3 into the lateral ventricles of prepubertal female rats twice a day for 8 days (from PND 28 to PND 36). To evaluate pubertal development, we observed the vaginal opening time, uterus and ovary development, and serum levels of sexual hormone. To explore the mechanism of action of RFRP-3, we detected the expression of hypothalamic Kiss-1 and GnRH mRNA. The status of the vaginal opening is a universally acknowledged external marker of female puberty onset in rodents. Our data show that ICV injection of RFRP-3 significantly delay the timing of puberty onset, characterized by delayed vaginal opening time and uterine development; it also reduce the serum levels of LH and E2. Recently, several findings suggested that endogenous RFRP-3 signaling may not be necessary for the timing of puberty [34, 35]. Pubertal analyses of null mice evidenced that GPR147 KO males, but not females, displayed constitutively elevated LH levels before and during puberty, whereas pubertal progression was not apparently altered by the congenital lack of GPR147 in either sex [35]. In accordance with this suggestion, a human genetics study revealed that the presence of variants in the genes encoding RFRP-3 and GPR147 is not associated with the occurrence of GnRH-pubertal disorders [34]. However, a 2015 study, by Semaan and Kauffman, showed a decrease in RFRP-3 expression in the hypothalamic dorsomedial nucleus during the prepubertal stage in mice [37]. This suggests that this decrease may disinhibit GnRH secretion and that RFRP-3 may be a possible inhibitory control during the onset of puberty. Consistent with that study, our results suggest that RFRP-3 delays the timing of puberty when administered exogenously, indicating that this peptide may play a significant role in sexual maturation and development.

Johnson et al. showed that ICV injection of RFRP-3 for 2 weeks reduced the levels of LH and wet weight of testes, but had no effect on puberty onset, in 35 day-old male rats [38]. The discrepancy in the results could be attributed to gender differences and/or to the RFRP-3 doses. Firstly, female rats were used in our study while male rats were used in the Johnson study. This raises questions on the possible sex-dependent differences in the role of RFRP-3 in the regulation of puberty onset. However, due to differences in experimental design, direct comparisons cannot be interpreted with confidence. Secondly, the dose of RFRP-3 was 1ug/day in our study and 15ug/day (15 times, 15 nmol/day, molecular weight: 990.15) in the Johnson study. In the past decade, numerous studies about RFRP-3 have been conducted in a variety of species with different developmental stages, different routes of administration, different doses, various treatment duration and also different molecules [either RFRP-3 (3-8) or entire molecules] [24, 27, 39, 40]. Several studies have demonstrated that injection of RFRP-3 decreases serum LH levels in a dose-dependent manner within a certain range [27, 39, 40]. However, higher doses can be ineffective on LH concentrations [24, 39]. Similarly, while the inhibitory action of RFRP-3 was observed at low RFRP-3 concentrations on GnRH stimulated LH secretion from pituitary cells, high concentrations had no effect [40]. So the relationship between the dose of RFRP-3 and inhibitory action on LH is more complicated than we anticipated. The use of different doses may be one of the reasons for the inconsistent results on with respect to the timing of puberty onset observed in Johnson’s study and the present results. Therefore, it is necessary to further investigate the relationship between different doses of RFRP-3 and the timing of puberty onset.

The various mechanisms, by which RFRP-3 may regulate the pubertal development, are not fully known. Previous findings suggested that RFRP-3 may directly or indirectly affect pituitary gonadotrophins and hypothalamic GnRH to regulate the reproductive axis. The Kiss-1 gene has been shown to be critical for the onset of puberty [19]. To determine whether Kiss-1 is a target for the central action of RFRP-3 in female rats, we examined Kiss-1 and GnRH mRNA expression in the hypothalamus. Accordingly, our data revealed that Kiss-1 and GnRH mRNA expression were significantly decreased in the RFRP-3 group. This raises a possibility that ICV RFRP-3 delays the timing of puberty onset in female rats mainly via a decrease in Kiss-1 expression, which is supported by several previous studies. RFRP-3 has been functionally shown to inhibit the electrical firing of some arcuate nucleus (ARC) kisspeptin neurons [41]. Rizwan et al. revealed that RFRP-3 can act at the rostral periventricular nucleus (PeN) kisspeptin and GnRH neurons to modulate reproduction, suggesting that RFRP-3 may directly regulate this kisspeptin population [28]. However, Poling’s study showed that RFRP-3 may directly modulate hypothalamic Kiss-1 neurons in mice but just a small proportion in the ARC [42]. They thought that the Kiss-1 and RFRP-3 likely act independently on the GnRH-pituitary axis and only have notable communication with each other at the level of RFRP-3 signaling to the ARC kisspeptin cells. Therefore, whether Kiss-1 is a major action site of RFRP-3 in the regulation of pubertal development is still controversial. Additionally, in our study, we excised the whole hypothalamus and measured whole hypothalamic Kiss-1 mRNA using RT-qPCR. It is preferable to separately measure the two primary kisspeptin populations of hypothalamic AVPV/PeN as well as ARC. Because of the limitation of our approach and the sophisticated molecular mechanisms of RFRP-3 regulatory actions, the various mechanisms involved in RFRP-3 mediated delay of pubertal timing are not fully known and require further investigation.

In our study, ICV RFRP-3 led to reduced secretion of LH and E2, but elevated FSH levels. This may be because RFRP-3 has no effect on FSH secretion; a single injection of RFRP-3 into lateral ventricular, or repeated injections for 14 days, affected LH levels, but had no effect on FSH levels, in adult male rats [27, 38]. This may be attributed to the time point of sample collection, which may not be optimal for the stimulation of FSH in rats. Another possible explanation for the decreased LH and increased FSH in the RFRP-3 group is a decreased GnRH pulse generator. The GnRH pulse generator is an important factor in regulating differential gonadotropin synthesis and secretion [43]. During the process of pubertal maturation, the responsiveness of LH and FSH to GnRH changes [43]. Before puberty, the predominant response is one of FSH secretion, while after puberty LH responses exceed those of FSH [43]. A decreased GnRH pulse generator in the group stimulated with RFRP-3 favors FSH secretion. Additionally, FSH levels remain constant during the onset of puberty (from PND15 to PND32) and decrease from PND32 to PND40 in normal Sprague-Dawley female rats [44]. These data may explain why FSH concentrations were higher in the RFRP-3 group than in the Vehicle group. These are also possible reasons for the delayed puberty onset and low uterine maturity, but normal ovarian maturity, in the RFRP-3 group; the uterus weight and morphology, not the ovary, are significantly changed during pubertal development in normal female rats. Studies show that the coefficient of the uterus, not the ovary, is significantly elevated in normal female rats between PND25 and PND40 [44]. On PND32 and PND40, the corpora lutea in rats are formed, and there is no significant difference in the number, indicating that no morphological changes occur during this period [44]. Thus, it is possible that RFRP-3 affects the time of puberty onset and the maturation of the uterus and ovaries, with a greater effect on the uterus. Additionally, puberty, a dynamic process of maturation of a young into a sexually mature adult, is controlled by a sophisticated network of regulatory signals. Our data suggest that RFRP-3 delays, but does not prevent the onset of puberty; therefore, it has limited effects on pubertal development. RFRP-3 may delay ovarian development, but not affect its final maturation.

Previous studies have shown that GHRH neurons are found in close apposition to the RFRP-3 neuron fibers in the hypothalamus, suggesting a possible functional relationship between them [27]. Of note, we found that RFRP-3 significantly promoted GH secretion. The serum GH level was significantly elevated 30 min after the last administration of RFRP-3 into the lateral ventricle, which was consistent with the data from Johnson in adult and 35 day-old male rats [38]. These results suggest that RFRP-3 may be an important regulator of growth during pubertal development in female rats. Gonadotropin releasing hormone analogue (GnRHa) has been used to treat precocious puberty; however, it alters the levels of GH, and then slows down the growth velocity [4547]. GH and GnRHa combination therapy has been used to improve final height, but this therapy is costly [48]. In our study, RFRP-3 not only delayed puberty onset but also promoted the secretion of GH in female rats, which may provide a novel method for the treatment of precocious puberty.

Conclusions

Our study is the first to reveal that ICV injection of RFRP-3 of prepubertal female rats can delay the timing of puberty onset. These results challenge the current notion of RFRP-3 exerting secondary, modulatory effects on mammalian puberty. This may not be as universal as previously assumed, as RFRP-3 appears to play a significant role in pubertal development. Additionally, RFRP-3 inhibited the central expression of hypothalamic Kiss-1 mRNA, suggesting that Kiss-1 may be one of the action sites in RFRP-3-delayed puberty onset. Moreover, in line with previous studies, we found that injection of RFRP-3 elevated the serum levels of GH, indicating that RFRP-3 can modulate the secretion of GH. These results suggest that RFRP-3 may be an important regulator for individual growth during pubertal development. Nevertheless, further research is needed to better characterize the specific mechanisms through which RFRP-3 delays the onset of puberty and alters the secretion of GH.

Abbreviations

APVP: 

Anteroventral periventricular nucleus

ARC: 

Arcuate nucleus

E2: 

Estradiol

FSH: 

Follicle-Stimulating Hormone

GAPDH: 

Glyceraldehyde-3-phosphate dehydrogenase

GH: 

Growth hormone

GHRH: 

Growth hormone-releasing hormone

GnIH: 

Gonadotropin-inhibitory hormone

GnRH: 

Gonadotropin-releasing hormone

GnRHa: 

Gonadotropin releasing hormone analogue.

GPR54: 

G protein-coupled receptor 54

HE: 

Hematoxylin-eosin

ICV: 

Intracerebroventricular

KO: 

Knockout

LH: 

Luteinizing Hormone

NKB: 

Neurokinin B

NPY: 

Neuropeptide Y

PE: 

Polyethylene

PeN: 

Rostral periventricular nucleus

PND: 

Postnatal day

RFRP-3: 

RFamide-related peptide-3

RT-qPCR: 

Real-time Quantitative Polymerase Chain Reaction

SP: 

Substance P

VO: 

Vaginal opening

Declarations

Acknowledgements

The authors would like to thank Prof. Yumin Shi for assistance and guidance.

Funding

This study was supported by the National Natural Science Foundation of China (No.81373692 to Jian Yu and No.81273804 to Yonghong Wang).

Availability of data and materials

The data used during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

XH, JY, and YW conceived of the study and participated in its design and coordination. XH performed the experiments, and the statistical analysis. YH and GZ participated in the experiments execution. WS, JL, and SY assisted in data analysis and helped prepare the manuscript. XH drafted the manuscript. JY revised the manuscript. All the authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval

This study was approved by the ethics committee of the Pediatric Research Ethics Board of Clinical Pharmacology Base, Fudan University (NO.: [2013]050).

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Integrative Medicine, Children’s Hospital of Fudan University
(2)
Department of Pediatrics, Xiamen Hospital of T.C.M

References

  1. Grumbach MM. The neuroendocrinology of human puberty revisited. Horm Res. 2002;57 Suppl 2:2–14.PubMedGoogle Scholar
  2. Ojeda SR, Lomniczi A, Mastronardi C, Heger S, Roth C, Parent AS, Matagne V, Mungenast AE. Minireview: the neuroendocrine regulation of puberty: is the time ripe for a systems biology approach? Endocrinology. 2006;147:1166–74.View ArticlePubMedGoogle Scholar
  3. Kauffman AS. Coming of age in the kisspeptin era: sex differences, development, and puberty. Mol Cell Endocrinol. 2010;324:51–63.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Richter LM. Studying adolescence. Science. 2006;312:1902–5.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Tena-Sempere M. Deciphering puberty: novel partners, novel mechanisms. Eur J Endocrinol. 2012;167:733–47.View ArticlePubMedGoogle Scholar
  6. Terasawa E, Guerriero KA, Plant TM. Kisspeptin and puberty in mammals. Adv Exp Med Biol. 2013;784:253–73.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Han SK, Gottsch ML, Lee KJ, Popa SM, Smith JT, Jakawich SK, Clifton DK, Steiner RA, Herbison AE. Activation of gonadotropin-releasing hormone neurons by kisspeptin as a neuroendocrine switch for the onset of puberty. J Neurosci. 2005;25:11349–56.View ArticlePubMedGoogle Scholar
  8. Rhie YJ. Kisspeptin/G protein-coupled receptor-54 system as an essential gatekeeper of pubertal development. Ann Pediatr Endocrinol Metab. 2013;18:55–9.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Pralong FP. Insulin and NPY pathways and the control of GnRH function and puberty onset. Mol Cell Endocrinol. 2010;324:82–6.View ArticlePubMedGoogle Scholar
  10. Sheffer-Babila S, Sun Y, Israel DD, Liu SM, Neal-Perry G, Chua SJ. Agouti-related peptide plays a critical role in leptin’s effects on female puberty and reproduction. Am J Physiol Endocrinol Metab. 2013;305:E1512–20.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Simavli S, Thompson IR, Maguire CA, Gill JC, Carroll RS, Wolfe A, Kaiser UB, Navarro VM. Substance p regulates puberty onset and fertility in the female mouse. Endocrinology. 2015;156:2313–22.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Li SY, Li XF, Hu MH, Shao B, Poston L, Lightman SL, O’Byrne KT. Neurokinin B receptor antagonism decreases luteinising hormone pulse frequency and amplitude and delays puberty onset in the female rat. J Neuroendocrinol. 2014;26:521–7.View ArticlePubMedGoogle Scholar
  13. Topaloglu AK, Reimann F, Guclu M, Yalin AS, Kotan LD, Porter KM, Serin A, Mungan NO, Cook JR, Ozbek MN, et al. TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for Neurokinin B in the central control of reproduction. Nat Genet. 2009;41:354–8.View ArticlePubMedGoogle Scholar
  14. Billings HJ, Connors JM, Altman SN, Hileman SM, Holaskova I, Lehman MN, McManus CJ, Nestor CC, Jacobs BH, Goodman RL. Neurokinin B acts via the neurokinin-3 receptor in the retrochiasmatic area to stimulate luteinizing hormone secretion in sheep. Endocrinology. 2010;151:3836–46.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Poling MC, Kauffman AS. Regulation and Function of RFRP-3 (GnIH) Neurons during Postnatal Development. Front Endocrinol (Lausanne). 2015;6:150.Google Scholar
  16. Tena-Sempere M. GPR54 and kisspeptin in reproduction. Hum Reprod Update. 2006;12:631–9.View ArticlePubMedGoogle Scholar
  17. Navarro VM, Castellano JM, Fernandez-Fernandez R, Barreiro ML, Roa J, Sanchez-Criado JE, Aguilar E, Dieguez C, Pinilla L, Tena-Sempere M. Developmental and hormonally regulated messenger ribonucleic acid expression of KiSS-1 and its putative receptor, GPR54, in rat hypothalamus and potent luteinizing hormone-releasing activity of KiSS-1 peptide. Endocrinology. 2004;145:4565–74.View ArticlePubMedGoogle Scholar
  18. Kuohung W, Kaiser UB. GPR54 and KiSS-1: role in the regulation of puberty and reproduction. Rev Endocr Metab Disord. 2006;7:257–63.View ArticlePubMedGoogle Scholar
  19. Kaiser UB, Kuohung W. KiSS-1 and GPR54 as new players in gonadotropin regulation and puberty. Endocrine. 2005;26:277–84.View ArticlePubMedGoogle Scholar
  20. Shahab M, Mastronardi C, Seminara SB, Crowley WF, Ojeda SR, Plant TM. Increased hypothalamic GPR54 signaling: a potential mechanism for initiation of puberty in primates. Proc Natl Acad Sci U S A. 2005;102:2129–34.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Seminara SB, Messager S, Chatzidaki EE, Thresher RR, Acierno JJ, Shagoury JK, Bo-Abbas Y, Kuohung W, Schwinof KM, Hendrick AG, et al. The GPR54 gene as a regulator of puberty. N Engl J Med. 2003;349:1614–27.View ArticlePubMedGoogle Scholar
  22. Tsutsui K, Saigoh E, Ukena K, Teranishi H, Fujisawa Y, Kikuchi M, Ishii S, Sharp JP. A novel avian hypothalamic peptide inhibiting gonadotropin release. Biochem Bioph Res Co. 2000;275:661–7.View ArticleGoogle Scholar
  23. Hinuma S, Shintani Y, Fukusumi S, Iijima N, Matsumoto Y, Hosoya M, Fujii R, Watanabe T, Kikuchi K, Terao Y, et al. New neuropeptides containing carboxy-terminal RFamide and their receptor in mammals. Nat Cell Biol. 2000;2:703–8.View ArticlePubMedGoogle Scholar
  24. Anderson GM, Relf HL, Rizwan MZ, Evans JJ. Central and peripheral effects of RFamide-related peptide-3 on luteinizing hormone and prolactin secretion in rats. Endocrinology. 2009;150:1834–40.View ArticlePubMedGoogle Scholar
  25. Kriegsfeld LJ, Mei DF, Bentley GE, Ubuka T, Mason AO, Inoue K, Ukena K, Tsutsui K, Silver R. Identification and characterization of a gonadotropin-inhibitory system in the brains of mammals. Proc Natl Acad Sci U S A. 2006;103:2410–5.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Ubuka T, Morgan K, Pawson AJ, Osugi T, Chowdhury VS, Minakata H, Tsutsui K, Millar RP, Bentley GE. Identification of human GnIH homologs, RFRP-1 and RFRP-3, and the cognate receptor, GPR147 in the human hypothalamic pituitary axis. PLoS One. 2009;4:e8400.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Johnson MA, Tsutsui K, Fraley GS. Rat RFamide-related peptide-3 stimulates GH secretion, inhibits LH secretion, and has variable effects on sex behavior in the adult male rat. Horm Behav. 2007;51:171–80.View ArticlePubMedGoogle Scholar
  28. Rizwan MZ, Poling MC, Corr M, Cornes PA, Augustine RA, Quennell JH, Kauffman AS, Anderson GM. RFamide-Related Peptide-3 Receptor Gene Expression in GnRH and Kisspeptin Neurons and GnRH-Dependent Mechanism of Action. Endocrinology. 2012;153:3770–9.View ArticlePubMedGoogle Scholar
  29. Losa-Ward SM, Todd KL, McCaffrey KA, Tsutsui K, Patisaul HB. Disrupted organization of RFamide pathways in the hypothalamus is associated with advanced puberty in female rats neonatally exposed to bisphenol A. Biol Reprod. 2012;87:28.View ArticlePubMedPubMed CentralGoogle Scholar
  30. Ubuka T, Inoue K, Fukuda Y, Mizuno T, Ukena K, Kriegsfeld LJ, Tsutsui K. Identification, expression, and physiological functions of Siberian hamster gonadotropin-inhibitory hormone. Endocrinology. 2012;153:373–85.View ArticlePubMedGoogle Scholar
  31. Bentley GE, Ubuka T, McGuire NL, Calisi R, Perfito N, Kriegsfeld LJ, Wingfield JC, Tsutsui K. Gonadotrophin-inhibitory hormone: a multifunctional neuropeptide. J Neuroendocrinol. 2009;21:276–81.View ArticlePubMedGoogle Scholar
  32. Murakami M, Matsuzaki T, Iwasa T, Yasui T, Irahara M, Osugi T, Tsutsui K. Hypophysiotropic role of RFamide-related peptide-3 in the inhibition of LH secretion in female rats. J Endocrinol. 2008;199:105–12.View ArticlePubMedGoogle Scholar
  33. Sari IP, Rao A, Smith JT, Tilbrook AJ, Clarke IJ. Effect of RF-amide-related peptide-3 on luteinizing hormone and follicle-stimulating hormone synthesis and secretion in ovine pituitary gonadotropes. Endocrinology. 2009;150:5549–56.View ArticlePubMedGoogle Scholar
  34. Lima C, Cardoso SC, Lemos E, Zingler E, Capanema C, Menezes LD, Vogado G, Dos Santos B, de Moraes OL, Duarte EF, et al. Mutational Analysis of the Genes Encoding RFAmide-Related Peptide-3, the Human Orthologue of Gonadotrophin-Inhibitory Hormone, and its Receptor (GPR147) in Patients with Gonadotrophin-Releasing Hormone-Dependent Pubertal Disorders. J Neuroendocrinol. 2014;26:817–24.View ArticlePubMedGoogle Scholar
  35. Leon S, Garcia-Galiano D, Ruiz-Pino F, Barroso A, Manfredi-Lozano M, Romero-Ruiz A, Roa J, Vazquez MJ, Gaytan F, Blomenrohr M, et al. Physiological Roles of Gonadotropin-Inhibitory Hormone Signaling in the Control of Mammalian Reproductive Axis: Studies in the NPFF1 Receptor Null Mouse. Endocrinology. 2014;155:2953–65.View ArticlePubMedGoogle Scholar
  36. Xiang W, Zhang B, Lv F, Ma Y, Chen H, Chen L, Yang F, Wang P, Chu M. The Inhibitory Effects of RFamide-Related Peptide 3 on Luteinizing Hormone Release Involves an Estradiol-Dependent Manner in Prepubertal but Not in Adult Female Mice. Biol Reprod. 2015;93:30.View ArticlePubMedGoogle Scholar
  37. Semaan SJ, Kauffman AS. Daily successive changes in reproductive gene expression and neuronal activation in the brains of pubertal female mice. Mol Cell Endocrinol. 2015;401:84–97.View ArticlePubMedGoogle Scholar
  38. Johnson MA, Fraley GS. Rat RFRP-3 Alters Hypothalamic GHRH Expression and Growth Hormone Secretion but Does Not Affect KiSS-1 Gene Expression or the Onset of Puberty in Male Rats. Neuroendocrinology. 2008;88:305–15.View ArticlePubMedGoogle Scholar
  39. Ancel C, Bentsen AH, Sebert ME, Tena-Sempere M, Mikkelsen JD, Simonneaux V. Stimulatory effect of RFRP-3 on the gonadotrophic axis in the male Syrian hamster: the exception proves the rule. Endocrinology. 2012;153:1352–63.View ArticlePubMedGoogle Scholar
  40. Pineda R, Garcia-Galiano D, Sanchez-Garrido MA, Romero M, Ruiz-Pino F, Aguilar E, Dijcks FA, Blomenrohr M, Pinilla L, van Noort PI, Tena-Sempere M. Characterization of the inhibitory roles of RFRP3, the mammalian ortholog of GnIH, in the control of gonadotropin secretion in the rat: in vivo and in vitro studies. Am J Physiol Endocrinol Metab. 2010;299:E39–46.View ArticlePubMedGoogle Scholar
  41. Fu LY, van den Pol AN. Kisspeptin directly excites anorexigenic proopiomelanocortin neurons but inhibits orexigenic neuropeptide Y cells by an indirect synaptic mechanism. J Neurosci. 2010;30:10205–19.View ArticlePubMedPubMed CentralGoogle Scholar
  42. Poling MC, Quennell JH, Anderson GM, Kauffman AS. Kisspeptin Neurones do not Directly Signal to RFRP-3 Neurones but RFRP-3 may Directly Modulate a Subset of Hypothalamic Kisspeptin Cells in Mice. J Neuroendocrinol. 2013;25:876–86.View ArticlePubMedPubMed CentralGoogle Scholar
  43. Marshall JC, Dalkin AC, Haisenleder DJ, Griffin ML, Kelch RP. GnRH pulses--the regulators of human reproduction. Trans Am Clin Climatol Assoc. 1993;104:31–46.PubMedPubMed CentralGoogle Scholar
  44. Dai FW, et al. Dynamic Development of Organs and Serum Sex Hormone Levels in Normal Pre-pubertal Female Sprague-Dawley Rats. Chin J Comp Med. 2009;19(07):33–8. In Chinese with English Abstract.Google Scholar
  45. van der Kaay DC, Rose SR, van Dijk M, Noordam C, van Rheenen E, Hokken-Koelega AC. Reduced levels of GH during GnRH analogue treatment in pubertal short girls born small for gestational age (SGA). Clin Endocrinol (Oxf). 2009;70:914–9.View ArticleGoogle Scholar
  46. Carel JC, Hay F, Coutant R, Rodrigue D, Chaussain JL. Gonadotropin-releasing hormone agonist treatment of girls with constitutional short stature and normal pubertal development. J Clin Endocrinol Metab. 1996;81:3318–22.PubMedGoogle Scholar
  47. Saggese G, Bertelloni S, Baroncelli GI, Di Nero G, Battini R. Growth velocity and serum aminoterminal propeptide of type III procollagen in precocious puberty during gonadotropin-releasing hormone analogue treatment. Acta Paediatr. 1993;82:261–6.View ArticlePubMedGoogle Scholar
  48. Tato L, Saggese G, Cavallo L, Antoniazzi F, Corrias A, Pasquino AM, Cisternino M. Use of combined Gn-RH agonist and hGH therapy for better attining the goals in precocious puberty treatment. Horm Res. 1995;44 Suppl 3:49–54.PubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement